Literature DB >> 22328537

Quality of life in adults with juvenile-onset dermatomyositis: a case-control study.

Anita Tollisen1, Helga Sanner, Berit Flatø, Astrid K Wahl.   

Abstract

OBJECTIVE: To compare quality of life in adults diagnosed with juvenile dermatomyositis (DM) with that of matched controls, and to analyze the association with other disease parameters in patients.
METHODS: Thirty-nine patients with juvenile DM (ages ≥ 18 years) were clinically examined and compared with 39 age- and sex-matched controls. Global and health-related quality of life (HRQOL) were assessed by the Norwegian version of the Quality of Life Scale (QOLS-N) and the Short Form 36 (SF-36), respectively. For patients, disease parameters were assessed by the Disease Activity Score (DAS), Health Assessment Questionnaire (HAQ), and Myositis Damage Index (MDI).
RESULTS: Compared to the controls, patients with juvenile DM assessed a median of 22.2 years (range 1.8-36.1 years) after disease onset had reduced HRQOL in general health (P = 0.009) measured by the SF-36. In patients, a moderate correlation was found between the physical component summary (PCS) score and the DAS (r(s) = -0.422) and MDI (r(s) = -0.381), and a strong correlation was found between the PCS score and the HAQ (r(s) = -0.516). There were no differences between patients and controls in the SF-36 mental component summary scores. Patients and controls had similar total scores of the QOLS-N, but differences existed within certain items.
CONCLUSION: Adult patients with juvenile DM had, compared to controls, reduced HRQOL in general health measured by the SF-36, but not in the other subscales of the SF-36 or in global quality of life measured by the QOLS-N. An association was found between disease parameters and reduced HRQOL in the physical domains.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2012        PMID: 22328537     DOI: 10.1002/acr.21637

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  7 in total

1.  Comparison of outcomes in adults with pediatric-onset morphea and those with adult-onset morphea: a cross-sectional study from the morphea in adults and children cohort.

Authors:  Daniel Condie; Daniel Grabell; Heidi Jacobe
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

2.  Long-term outcomes in Juvenile Myositis patients.

Authors:  Vladislav Tsaltskan; Annette Aldous; Sam Serafi; Anna Yakovleva; Heidi Sami; Gulnara Mamyrova; Ira N Targoff; Adam Schiffenbauer; Frederick W Miller; Samuel J Simmens; Rodolfo Curiel; Olcay Y Jones; Lisa G Rider
Journal:  Semin Arthritis Rheum       Date:  2019-06-28       Impact factor: 5.532

Review 3.  Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis.

Authors:  Silvia Rosina; Giulia Camilla Varnier; Marta Mazzoni; Stefano Lanni; Clara Malattia; Angelo Ravelli
Journal:  Curr Rheumatol Rep       Date:  2018-04-10       Impact factor: 4.592

4.  213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015.

Authors:  Olivier Benveniste; Lisa G Rider
Journal:  Neuromuscul Disord       Date:  2016-05-27       Impact factor: 4.296

5.  Comparison of Patient-Reported Outcomes Measurement Information System Computerized Adaptive Testing Versus Fixed Short Forms in Juvenile Myositis.

Authors:  Ruchi N Patel; Valeria G Esparza; Jin-Shei Lai; Elizabeth L Gray; Bryce B Reeve; Rowland W Chang; David Cella; Kaveh Ardalan
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-07-30       Impact factor: 5.178

6.  Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus.

Authors:  Mathilda Björk; Örjan Dahlström; Jonas Wetterö; Christopher Sjöwall
Journal:  BMC Musculoskelet Disord       Date:  2015-08-12       Impact factor: 2.362

Review 7.  Update in juvenile myositis.

Authors:  Kiran Nistala; Lucy R Wedderburn
Journal:  Curr Opin Rheumatol       Date:  2013-11       Impact factor: 5.006

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.